[Sub-classification of diffuse large B-cell lymphoma by semi-quantification of the CD5 expression with flow cytometric analysis].
CD5+ diffuse large B-cell lymphoma(CD5+DLBCL) is known to have different characteristics than CD5-DLBCL and mantle cell lymphoma(MCL). 9 patients with CD5+DLBCL were reviewed, and the results were compared with those of 8 CD5-DLBCL and 3 cyclin D1+MCL patients. CD5+DLBCL was more closely related to many aggressive clinical features or parameters than CD5-DLBCL: 67% of the patients were older than 60 years, 67% with performance status > or = 2, 89% with serum lactate dehydrogenase level higher than normal, 78% with stage III/IV disease at diagnosis, and 78% with more than one extranodal lesion. The overall International Prognostic Index score for the patients with CD5+DLBCL was thus significantly higher than that for those with CD5-DLBCL. Immunophenotypically, CD5+DLBCL was characterized by CD5+CD10-CD19+CD20+CD21-CD23-cyclin D1-phenotype and the predominant expression of surface IgM. Of particular interest is that the survival rate of CD5+DLBCL patients was significantly inferior to that of patients with CD5-DLBCL. To further characterize CD5+DLBCL, we semi-quantified the CD5 expression in DLBCL cells. Our findings suggest that CD5+DLBCL may constitute a unique subgroup of DLBCL and, moreover, CD5+DLBCL may consist of several subgroups.
Manabe
Noriko
N
Department of Medical Technology, Kagawa Prefectural College of Health Sciences, Kida-gun, Kagawapref, 761-0123.
Yamaoka
Genji
G
Ohnishi
Hiroaki
H
Arai
Takeshi
T
Nakaishi
Hiromi
H
Kajikawa
Tatushi
T
Kubota
Yoshitsugu
Y
Tanaka
Terukazu
T
Kitanaka
Akira
A
Waki
Masato
M
Kawakami
Kimihiro
K
Nagai
Masami
M
Ishida
Toshihiko
T
Taminato
Tomohiko
T
D000368:Aged; D000369:Aged, 80 and over; D018956:CD5 Antigens / Q000032:analysis*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016393:Lymphoma, B-Cell / Q000145:classification* / Q000401:mortality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate
D018956:CD5 Antigens